260 related articles for article (PubMed ID: 27976632)
21. Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy.
Li B; Duan L; Shi J; Han Y; Wei W; Cheng X; Cao Y; Kader A; Ding D; Wu X; Gao Y
Front Oncol; 2022; 12():1072437. PubMed ID: 36568205
[TBL] [Abstract][Full Text] [Related]
22. Comparison of hybrid
Janssen JC; Meißner S; Woythal N; Prasad V; Brenner W; Diederichs G; Hamm B; Makowski MR
Eur Radiol; 2018 Feb; 28(2):610-619. PubMed ID: 28779400
[TBL] [Abstract][Full Text] [Related]
23. Clinical Impact of 68Ga-PSMA PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer.
Queiroz MA; Viana P; Santos A; Bastos D; Etchebehere E; Cerri G
Clin Nucl Med; 2016 Sep; 41(9):e417-9. PubMed ID: 27276202
[TBL] [Abstract][Full Text] [Related]
24. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
25. 99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
Schmidkonz C; Atzinger A; Goetz TI; Beck M; Ritt P; Prante O; Kuwert T; Bäuerle T; Cordes M
Clin Nucl Med; 2020 Feb; 45(2):105-112. PubMed ID: 31876822
[TBL] [Abstract][Full Text] [Related]
26. Head-to-head comparison of
Zhang Y; Lin Z; Li T; Wei Y; Yu M; Ye L; Cai Y; Yang S; Zhang Y; Shi Y; Chen W
Sci Rep; 2022 Sep; 12(1):15993. PubMed ID: 36163353
[TBL] [Abstract][Full Text] [Related]
27. Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
Liu C; Zhu Y; Su H; Xu X; Zhang Y; Song S; Wang B; Ye D; Hu S
Cancer Med; 2020 May; 9(10):3278-3286. PubMed ID: 32163676
[TBL] [Abstract][Full Text] [Related]
28. Integrated
Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
[TBL] [Abstract][Full Text] [Related]
29. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
30. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
31. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
32. First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer.
Reinfelder J; Kuwert T; Beck M; Sanders JC; Ritt P; Schmidkonz C; Hennig P; Prante O; Uder M; Wullich B; Goebell P
Clin Nucl Med; 2017 Jan; 42(1):26-33. PubMed ID: 27775936
[TBL] [Abstract][Full Text] [Related]
33.
Henkenberens C; VON Klot CA; Ross TL; Bengel FM; Wester HJ; Katja H; Christiansen H; Derlin T
Anticancer Res; 2017 Mar; 37(3):1273-1279. PubMed ID: 28314292
[TBL] [Abstract][Full Text] [Related]
34. Comparison of bone scintigraphy and
Pyka T; Okamoto S; Dahlbender M; Tauber R; Retz M; Heck M; Tamaki N; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
[TBL] [Abstract][Full Text] [Related]
35. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
36. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
37. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
38. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
[TBL] [Abstract][Full Text] [Related]
39. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
Vallabhajosula S; Nikolopoulou A; Babich JW; Osborne JR; Tagawa ST; Lipai I; Solnes L; Maresca KP; Armor T; Joyal JL; Crummet R; Stubbs JB; Goldsmith SJ
J Nucl Med; 2014 Nov; 55(11):1791-8. PubMed ID: 25342385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]